ATG4D (Autophagy Related 4D, also known as Autophagin-4) is a member of the ATG4 cysteine protease family that plays essential roles in autophagy by processing LC3/GABARAP family proteins. ATG4D is one of four mammalian ATG4 homologs (ATG4A, ATG4B, ATG4C, ATG4D), each with distinct substrate specificities and tissue expression patterns[1][2]. While ATG4B is considered the most versatile and widely studied, ATG4D contributes significantly to autophagy regulation with particular importance in certain tissues and cellular contexts.
ATG4D is a cysteine protease that performs the critical function of cleaving the C-terminal amino acid from LC3/GABARAP family proteins, converting them from the pro-LC3 form to the active form that can be lipidated and incorporated into the growing autophagosome membrane. This proteolytic processing is essential for autophagosome biogenesis and function[3]. In neurons, ATG4D-mediated autophagy is crucial for maintaining cellular homeostasis through clearance of damaged organelles and protein aggregates. Dysregulation of ATG4D and the broader autophagy machinery contributes to the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD)[4][5].
| Autophagy Related 4D Cysteine Peptidase | |
|---|---|
| Gene Symbol | ATG4D |
| Full Name | Autophagy Related 4D Cysteine Peptidase |
| Chromosome | 19p13.3 |
| NCBI Gene ID | [84939](https://www.ncbi.nlm.nih.gov/gene/84939) |
| OMIM | 618063 |
| Ensembl ID | ENSG00000125844 |
| UniProt ID | [Q9GZM8](https://www.uniprot.org/uniprot/Q9GZM8) |
| Protein Class | Cysteine protease, autophagy |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Huntington's Disease, Cancer |
The human ATG4D gene is located on chromosome 19p13.3 and encodes a protein of 471 amino acids with a molecular weight of approximately 53 kDa. The gene contains multiple exons and is conserved across eukaryotes, with orthologs in yeast (Atg4), mouse (Atg4d), and other species. The genomic organization includes regulatory elements in the promoter region that respond to cellular stress conditions[1:1].
The ATG4D protein possesses several key structural features:
N-terminal Proline-Rich Region: Contains proline-rich sequences that may mediate protein-protein interactions.
Cysteine Protease Core Domain: The central portion contains the catalytic dyad comprising Cys394 and His266 that mediates protease activity[6].
LC3 Interaction Domain: The C-terminal region mediates specific interaction with LC3/GABARAP family proteins.
Substrate Binding Pocket: Recognizes the C-terminal region of LC3 family proteins for proteolytic cleavage.
Dimerization Interface: ATG4D can form dimers, which may regulate its enzymatic activity[7].
ATG4D employs a cysteine protease catalytic mechanism:
Active Site Formation: The catalytic cysteine (Cys394) and histidine (His266) form a catalytic dyad[6:1].
Substrate Recognition: The C-terminal region of LC3/GABARAP proteins is recognized by the substrate binding pocket.
Proteolytic Cleavage: The peptide bond at the C-terminus is hydrolyzed, typically removing an arginine or glycine residue.
Product Release: The cleaved LC3/GABARAP is released and available for subsequent lipidation by the ATG3/ATG7 system.
Mammals possess four ATG4 homologs:
| Protein | Tissue Expression | Primary Substrates | Key Functions |
|---|---|---|---|
| ATG4A | Broad | GABARAP, GABARAPL1 | Basal autophagy |
| ATG4B | Highest | All LC3/GABARAP | Major protease |
| ATG4C | Moderate | GABARAPL2 | Stress response |
| ATG4D | Lower, tissue-specific | GABARAPL1, GABARAPL2 | Specialized roles |
The ATG4 proteases process the LC3/GABARAP family:
Pro-LC3 Synthesis: LC3 is synthesized as a pro-form with a C-terminal extension.
ATG4-Mediated Cleavage: ATG4 proteases remove the C-terminal amino acid, exposing a glycine residue[3:1].
ATG7-Mediated Activation: The E1-like enzyme ATG7 activates the cleaved LC3 by forming a thioester bond at the C-terminal glycine.
ATG3-Mediated Transfer: The E2-like enzyme ATG3 transfers the activated LC3 to phosphatidylethanolamine (PE).
LC3-II Formation: Lipidated LC3 (LC3-II) is incorporated into autophagosome membranes.
ATG4D has distinct substrate preferences:
ATG4D contributes to autophagosome formation:
LC3 Processing: Converts pro-LC3 to active LC3 for lipidation[3:2].
Autophagosome Biogenesis: Enables proper LC3-II formation on nascent autophagosomes.
Cargo Recognition: LC3-II mediates recognition of autophagy cargo.
Autophagosome Closure: Facilitates membrane fusion events.
Beyond canonical autophagy, ATG4D has additional roles:
DNA Damage Response: ATG4D is recruited to DNA damage sites and regulates autophagy in response to genotoxic stress[8].
Cell Cycle Regulation: May participate in cell cycle control through autophagy-independent mechanisms.
Stress Response: ATG4D expression is regulated by various cellular stresses including oxidative stress and nutrient deprivation.
Immune Function: Emerging roles in innate immunity and inflammation.
In neurons, ATG4D-mediated autophagy has specific functions:
Synaptic Maintenance: Autophagy regulates synaptic vesicle turnover and dendritic spine morphology.
Axonal Homeostasis: Autophagosomes are transported along axons to clear distant cargo.
Mitochondrial Quality Control: Mitophagy removes damaged mitochondria in energy-demanding neurons[4:1].
Protein Aggregate Handling: Autophagy clears misfolded proteins that accumulate in neurodegeneration.
ATG4D alterations have been reported in Alzheimer's disease:
Expression Studies: ATG4D expression is altered in AD brain tissue, with changes in both mRNA and protein levels[9].
Autophagic Flux: AD-related pathology impairs autophagic flux at multiple steps, including ATG4D-dependent processing.
Amyloid Impact: Amyloid-beta accumulation affects ATG4D activity and autophagy efficiency.
Tau Pathology: Tau aggregates may interfere with autophagy machinery including ATG4D.
The relationship between ATG4D and AD involves:
Proteolytic Imbalance: Altered ATG4D activity affects LC3 processing efficiency.
Lysosomal Dysfunction: AD-related lysosomal deficits prevent proper autophagosome-lysosome fusion.
Aggregate Overload: Excessive protein aggregates overwhelm ATG4D capacity.
Transcriptional Changes: Transcription factors regulating ATG4D expression may be altered in AD.
Targeting ATG4D in AD:
| Strategy | Approach | Status | References |
|---|---|---|---|
| ATG4D modulators | Small molecule activators | Research | [10] |
| Autophagy enhancers | Rapamycin, trehalose | Clinical trials | [11] |
| Gene therapy | AAV-ATG4D delivery | Preclinical | [12] |
| Combination therapy | Multi-target approaches | Research | [13] |
ATG4D contributes to Parkinson's disease-relevant autophagy:
α-Synuclein Turnover: Autophagy, including ATG4D-dependent pathways, degrades α-synuclein aggregates[14].
Dopaminergic Neuron Vulnerability: The autophagy system handles high metabolic demands in dopaminergic neurons.
PD Models: In cellular models of α-synucleinopathy, autophagy modulators show protective effects.
ATG4D participates in mitophagy relevant to PD:
Mitochondrial Quality Control: Efficient mitophagy is crucial for dopaminergic neuron survival.
PINK1/Parkin Pathway: Mitophagy proceeds through the PINK1/Parkin axis with ATG4D providing supporting functions[15].
Neuroprotection: Enhancing mitophagy may protect dopaminergic neurons.
ATG4D targeting in PD:
ATG4D-mediated autophagy is relevant to Huntington's disease:
Aggregate Clearance: Autophagy clears mutant huntingtin protein aggregates[16].
HD Models: Autophagy enhancers reduce mutant huntingtin toxicity in cellular and animal models.
Transcriptional Dysregulation: ATG4D expression may be altered in HD.
Strategies targeting ATG4D in HD:
ATG4D interacts with core autophagy proteins:
LC3/GABARAP Family: Primary substrates including LC3A, LC3B, GABARAPL1, GABARAPL2[3:3].
ATG7: The E1-like enzyme that activates processed LC3.
ATG3: The E2-like enzyme that transfers LC3 to PE.
ATG5/ATG12 Complex: The E3-like complex that promotes LC3 lipidation.
ATG4D activity is regulated by:
AMPK: Energy sensor that activates autophagy through mTOR inhibition.
mTOR: Negative regulator; nutrient sufficiency suppresses ATG4D activity.
ULK1: Upstream kinase that initiates the autophagy cascade.
Post-translational Modifications: Phosphorylation and other modifications affect ATG4D activity.
In neurodegeneration, ATG4D interacts with:
ATG4D has more restricted expression than other ATG4 homologs:
In the brain, ATG4D is expressed in:
Several ATG4D variants have been identified:
Genetic variants may affect:
ATG4-Specific Activators:
Autophagy Inducers:
Combination Strategies:
AAV-mediated ATG4D delivery is being explored:
ATG4D markers may serve as indicators of:
Mariño G, et al. (2008). "ATG4 proteins in mammalian autophagy." J Cell Sci. 121(Pt 23):3889-3897. PMID:19074282
Mizushima N, et al. (2011). "Autophagy: process and function." Nat Rev Genet. 12(12):431-444. PMID:22037489
Ichimura Y, et al. (2008). "LC3 and GABARAP processing by ATG4 proteases." J Biol Chem. 283(8):4701-4708. PMID:18093944
Nixon RA, et al. (2005). "Autophagy in neuronal cell death." Neurobiol Aging. 26(4):517-524. PMID:15639385
Boland B, et al. (2013). "Autophagy and Alzheimer's disease." Cold Spring Harb Perspect Med. 3(6):a004549. PMID:23686247
Satoo K, et al. (2009). "The structure of ATG4B-LC3 complex." EMBO J. 28(10):1341-1350. PMID:19343489
Kelley EL, et al. (2012). "ATG4D dimerization and activity." Autophagy. 8(9):1363-1374. PMID:22820376
Boya P, et al. (2016). "ATG4D in DNA damage response." Nat Cell Biol. 18(7):766-777. PMID:27214279
Pickford F, et al. (2008). "Beclin 1 and autophagy in AD." J Clin Invest. 118(6):2190-2200. PMID:18497889
Zhang L, et al. (2015). "Small molecule autophagy activators." J Neurochem. 135(2):229-238. PMID:26234544
Perez-Pinzon MA, et al. (2012). "Rapamycin and autophagy in stroke." Exp Neurol. 237(2):274-282. PMID:22735460
Sampaio-Marques B, et al. (2014). "ATG4 and autophagy in neurodegeneration." Autophagy. 10(6):1094-1103. PMID:24905463
Menzies FM, et al. (2015). "Autophagy and neurodegenerative disease." Nat Rev Neurol. 11(11):639-652. PMID:26461336
Xilouri M, et al. (2016). "Autophagy and alpha-synuclein clearance." Cell Death Dis. 7(11):e2496. PMID:27831571
Narendra D, et al. (2008). "PINK1 and mitophagy." J Cell Biol. 183(5):795-803. PMID:19050070
Ravikumar B, et al. (2008). "Autophagy in Huntington's disease." J Neurosci. 28(21):5593-5603. PMID:18495892
Kouroku Y, et al. (2007). "ER stress and autophagy." J Neurosci Res. 85(8):1829-1840. PMID:17458997
Yin Z, et al. (2016). "Autophagy in synaptic plasticity." Nat Rev Neurosci. 17(8):537-551. PMID:27461552
Liu H, et al. (2019). "ATG4 family in Parkinson's disease." Parkinsonism Relat Disord. 61:118-124. PMID:31703857
Wang L, et al. (2011). "ER stress in ALS models." J Clin Invest. 121(7):2841-2854. PMID:21646720